JP2013523821A - 前房内薬剤送達のための徐放性リザーバーインプラント - Google Patents

前房内薬剤送達のための徐放性リザーバーインプラント Download PDF

Info

Publication number
JP2013523821A
JP2013523821A JP2013503845A JP2013503845A JP2013523821A JP 2013523821 A JP2013523821 A JP 2013523821A JP 2013503845 A JP2013503845 A JP 2013503845A JP 2013503845 A JP2013503845 A JP 2013503845A JP 2013523821 A JP2013523821 A JP 2013523821A
Authority
JP
Japan
Prior art keywords
implant
antihypertensive
reservoir
polymer
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013503845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523821A5 (cg-RX-API-DMAC7.html
Inventor
ルーウェン・シ
パトリック・エム・ヒューズ
ジェイムズ・エイ・バーク
マイケル・アール・ロビンソン
フイ・リウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2013523821A publication Critical patent/JP2013523821A/ja
Publication of JP2013523821A5 publication Critical patent/JP2013523821A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013503845A 2010-04-06 2011-04-05 前房内薬剤送達のための徐放性リザーバーインプラント Pending JP2013523821A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32142210P 2010-04-06 2010-04-06
US61/321,422 2010-04-06
PCT/US2011/031265 WO2011127064A2 (en) 2010-04-06 2011-04-05 Sustained-release reservoir implants for intracameral drug delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015090706A Division JP2015166361A (ja) 2010-04-06 2015-04-27 前房内薬剤送達のための徐放性リザーバーインプラント

Publications (2)

Publication Number Publication Date
JP2013523821A true JP2013523821A (ja) 2013-06-17
JP2013523821A5 JP2013523821A5 (cg-RX-API-DMAC7.html) 2014-05-08

Family

ID=44065364

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013503845A Pending JP2013523821A (ja) 2010-04-06 2011-04-05 前房内薬剤送達のための徐放性リザーバーインプラント
JP2015090706A Pending JP2015166361A (ja) 2010-04-06 2015-04-27 前房内薬剤送達のための徐放性リザーバーインプラント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015090706A Pending JP2015166361A (ja) 2010-04-06 2015-04-27 前房内薬剤送達のための徐放性リザーバーインプラント

Country Status (10)

Country Link
US (3) US20130017243A1 (cg-RX-API-DMAC7.html)
EP (1) EP2555749B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013523821A (cg-RX-API-DMAC7.html)
KR (1) KR20130086131A (cg-RX-API-DMAC7.html)
CN (1) CN102905688B (cg-RX-API-DMAC7.html)
AU (1) AU2011237788A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012025581A2 (cg-RX-API-DMAC7.html)
CA (1) CA2795706A1 (cg-RX-API-DMAC7.html)
RU (1) RU2012146630A (cg-RX-API-DMAC7.html)
WO (1) WO2011127064A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529168A (ja) * 2020-06-03 2023-07-07 グラウコス コーポレイション Rhoキナーゼ阻害剤放出インプラントおよび関連する使用方法

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションDose Medical Corporation 薬剤溶出眼内インプラント
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
JP2013526572A (ja) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド 眼治療薬の送達のための薬物送達装置
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
EP3494959A3 (en) 2011-04-29 2019-09-11 Allergan, Inc. Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2014120866A1 (en) 2013-01-31 2014-08-07 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
EP2956096A1 (en) * 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
ES2751681T3 (es) * 2013-03-15 2020-04-01 Allergan Inc Implante intraocular que contiene prostamida
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
AU2014350095B9 (en) * 2013-11-14 2019-09-12 Eyed Pharma Eye device
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
BR112017007942A2 (pt) * 2014-10-30 2017-12-19 Textile Based Delivery Inc sistemas de liberação
CN104587850A (zh) * 2015-01-11 2015-05-06 王丽莉 一种聚偏氟乙烯中空纤维膜的制备方法
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
RU2620249C1 (ru) * 2015-12-17 2017-05-23 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Многослойный биодеградируемый глазной имплантат с дозированным высвобождением лекарственного вещества и способ его изготовления
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR102814241B1 (ko) 2016-09-23 2025-05-29 인셉트, 엘엘씨 전안방내 약물 전달 데포
EP3518844A4 (en) * 2016-09-30 2020-05-27 Lynthera Corporation HIGH PRECISION DRUG DELIVERY THROUGH A DUAL DOMAIN EYE DEVICE
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US11406533B2 (en) 2017-03-17 2022-08-09 W. L. Gore & Associates, Inc. Integrated aqueous shunt for glaucoma treatment
JP7770768B6 (ja) * 2017-10-13 2025-12-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 繊毛病に関連する疾患の治療方法
RU185437U1 (ru) * 2018-04-12 2018-12-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" Устройство для герметизации капсул алюминиевых
EP3793537A1 (en) * 2018-05-16 2021-03-24 Spirox, Inc. Allergic rhinitis drug delivery implant
EP3843676A1 (en) 2018-08-29 2021-07-07 W.L. Gore & Associates, Inc. Drug therapy delivery systems and methods
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11975087B2 (en) * 2020-03-30 2024-05-07 Colgate-Palmolive Company Sulfate-free personal care compositions and methods for preventing and treating pollution damage to skin
EP4021389A1 (en) 2020-03-30 2022-07-06 Colgate-Palmolive Company Personal care compositions
US20230338278A1 (en) * 2020-09-17 2023-10-26 The University Of North Carolina At Chapel Hill Methods, Systems and Devices for Post-Fabrication Drug Loading
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US12527691B2 (en) 2021-11-05 2026-01-20 W. L. Gore & Associates, Inc. Fluid drainage devices, systems, and methods
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物
USD1137672S1 (en) 2024-08-27 2026-07-28 Glaukos Corporation Drug eluting ocular implant

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530964A (ja) * 2000-04-26 2003-10-21 コントロール・デリバリー・システムズ・インコーポレイテッド 除放性薬剤送達システム、使用方法、およびその製造方法
JP2005532313A (ja) * 2002-05-07 2005-10-27 コントロール・デリバリー・システムズ・インコーポレイテッド 薬物送達装置の形成方法
JP2006516618A (ja) * 2003-01-24 2006-07-06 コントロール・デリバリー・システムズ・インコーポレイテッド アドレナリン作動薬を眼へ輸送するために徐放性デバイス及び方法
JP2006516621A (ja) * 2003-01-24 2006-07-06 コントロール・デリバリー・システムズ・インコーポレイテッド 高度に溶解性の薬剤の制御された放出
JP2007512248A (ja) * 2003-11-13 2007-05-17 シヴィダ インコーポレイテッド 生物浸食性マトリクスコア及び生物浸食性スキンを有する注射可能な持続的放出用の送達用デバイス
JP2009510109A (ja) * 2005-09-28 2009-03-12 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 自己組織化生分解性ポリマーソーム

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
TR200201047T2 (tr) * 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
EP1706095B1 (en) * 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20080299176A1 (en) * 2007-05-30 2008-12-04 Yu-Chin Lai Drug delivery device comprising crosslinked polyurethane-siloxane-containing copolymers
AU2008300013A1 (en) * 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
US20120245505A1 (en) * 2009-12-16 2012-09-27 Robinson Michael R Intracameral devices for sustained delivery

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530964A (ja) * 2000-04-26 2003-10-21 コントロール・デリバリー・システムズ・インコーポレイテッド 除放性薬剤送達システム、使用方法、およびその製造方法
JP2005532313A (ja) * 2002-05-07 2005-10-27 コントロール・デリバリー・システムズ・インコーポレイテッド 薬物送達装置の形成方法
JP2006516618A (ja) * 2003-01-24 2006-07-06 コントロール・デリバリー・システムズ・インコーポレイテッド アドレナリン作動薬を眼へ輸送するために徐放性デバイス及び方法
JP2006516621A (ja) * 2003-01-24 2006-07-06 コントロール・デリバリー・システムズ・インコーポレイテッド 高度に溶解性の薬剤の制御された放出
JP2007512248A (ja) * 2003-11-13 2007-05-17 シヴィダ インコーポレイテッド 生物浸食性マトリクスコア及び生物浸食性スキンを有する注射可能な持続的放出用の送達用デバイス
JP2009510109A (ja) * 2005-09-28 2009-03-12 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 自己組織化生分解性ポリマーソーム

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529168A (ja) * 2020-06-03 2023-07-07 グラウコス コーポレイション Rhoキナーゼ阻害剤放出インプラントおよび関連する使用方法
JP7689144B2 (ja) 2020-06-03 2025-06-05 グラウコス コーポレイション Rhoキナーゼ阻害剤放出インプラントおよび関連する使用方法

Also Published As

Publication number Publication date
JP2015166361A (ja) 2015-09-24
KR20130086131A (ko) 2013-07-31
AU2011237788A1 (en) 2012-11-01
CA2795706A1 (en) 2011-10-13
WO2011127064A2 (en) 2011-10-13
US20160256382A1 (en) 2016-09-08
CN102905688B (zh) 2015-11-25
US20130017243A1 (en) 2013-01-17
EP2555749A2 (en) 2013-02-13
BR112012025581A2 (pt) 2019-09-24
WO2011127064A3 (en) 2012-10-26
CN102905688A (zh) 2013-01-30
US20150104491A1 (en) 2015-04-16
EP2555749B1 (en) 2016-10-26
RU2012146630A (ru) 2014-05-20

Similar Documents

Publication Publication Date Title
JP2015166361A (ja) 前房内薬剤送達のための徐放性リザーバーインプラント
JP6946503B2 (ja) 眼房内ビマトプロスト注入物による眼圧低下
KR102126007B1 (ko) 전방내 서방성 치료제 이식물
JP5580832B2 (ja) 生分解性α−2アゴニストポリマー性インプラントおよびその治療用途
TW201012469A (en) Combination treatment of glaucoma
JP2024032731A (ja) 効果の持続期間が延長された眼内圧降下用徐放性インプラント
US20230026451A1 (en) Intraocular pressure reduction with intracameral bimatoprost implants
HK1181641A (en) Sustained-release reservoir implants for intracameral drug delivery
HK1244665B (en) Intraocular pressure reduction with intracameral prostamide implants
HK1244665A1 (en) Intraocular pressure reduction with intracameral prostamide implants
HK1183436A (en) Intraocular pressure reduction with intracameral bimatoprost implants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150707